

Nonclinical development of CTN001 for treating patients with breast cancer and gastric cancer

Centenaire Bioscience, Inc.



| ONCOLOGY | Preclinical |
|--------------------------|---|
| Product Type | Twin Fc-ICE antibody (Biopharmaceutical) |
| Indication | Trastuzumab, Pertuzumab or Enhertu-Refractory/relapsed Her2+ or Her2-low breast cancer AND gastric cancer(GC) |
| Target | HER2 |
| MoA(Mechanism of Action) | <ul style="list-style-type: none">Enhanced engagement of multiple innate immune cells and complements with HER2-expressing tumorsSuperior antibody-mediated functions (ADCC, ADCP/ADCT and CDC) |
| Competitiveness | <ul style="list-style-type: none">Innovative Twin Fc-ICE platform for engaging innate immune cells via increased binding to activating Fcγ receptors and Her2 expressing cancer cellsBest-in-class engineered antibody showing superior anti-tumor activity in HER2-low cancers as well as HER2+ cancersGood developability and safety, comparable to conventional IgG1Targeting Enhertu-refractory/relapsed HER2+ and HER2-low patients |
| Development Stage | Preclinical (Toxicology studies on-going) |
| Route of Administration | IV |